Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
36.05
-0.60 (-1.64%)
At close: Oct 8, 2026, 4:00 PM EDT
36.04
-0.01 (-0.03%)
After-hours: Oct 8, 2026, 7:30 PM EDT
Genmab Market Cap
Genmab has a market cap or net worth of $21.09 billion as of October 8, 2026. Its market cap has decreased by 1.30% in one year.
Market Cap
21.09B
Enterprise Value
24.78B
1-Year Change
-1.30%
Global Rank
n/a
Country Rank
n/a
Category
ChartMarket Cap Chart
Since April 23, 2012, Genmab's market cap has increased from $420.50M to $21.09B, an increase of 4,915.93%. That is a compound annual growth rate of 31.08%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 7, 2026 | 22.85B | 15.56% |
| Dec 31, 2025 | 19.78B | 43.19% |
| Dec 31, 2024 | 13.81B | -34.35% |
| Dec 29, 2023 | 21.04B | -24.60% |
| Dec 30, 2022 | 27.90B | 7.47% |
| Dec 31, 2021 | 25.96B | -1.89% |
| Dec 31, 2020 | 26.46B | 84.27% |
| Dec 31, 2019 | 14.36B | 35.31% |
| Dec 31, 2018 | 10.61B | -0.44% |
| Dec 29, 2017 | 10.66B | -0.04% |
| Dec 30, 2016 | 10.66B | 23.74% |
| Dec 31, 2015 | 8.62B | 128.70% |
| Dec 31, 2014 | 3.77B | 49.72% |
| Dec 31, 2013 | 2.52B | 179.56% |
| Dec 31, 2012 | 900.30M | 114.10% |
| Apr 23, 2012 | 420.50M | - |
View and export this data all the way back to 2012. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Royalty Pharma | 32.60B |
| Alnylam Pharmaceuticals | 30.30B |
| Roivant Sciences | 25.30B |
| BioNTech SE | 24.15B |
| Incyte | 22.99B |
| Insmed | 22.45B |
| Jazz Pharmaceuticals | 15.14B |
| Ascendis Pharma | 14.96B |